Aflibercept 8mg for neovascular age related macular degeneration refractory to faricimab
Japanese Journal of Ophthalmology · 22.07.2026
DOI: 10.1007/s10384-026-01407-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Japanese Journal of Ophthalmology, online erschienen am 22.07.2026. Verfasst von Juliana H Moribe und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology and Visual Science, Kochi Medical School, Kochi University, Kohasu, Oko, Nankoku, Kochi, 783-8505, Japan. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
To evaluate the short-term efficacy of intravitreal aflibercept 8 mg in patients with neovascular age-related macular degeneration (nAMD) who exhibited persistent or recurrent exudation two months after faricimab treatment during the maintenance phase following anti-vascular endothelial growth factor (VEGF) loading therapy. Study design Retrospective observational study.
Methods
Twenty-seven eyes with nAMD were included. Best-corrected visual acuity (BCVA) and optical coherence tomography (OCT) biomarkers—including intraretinal fluid (IRF), subretinal fluid (SRF), and sub–retinal pigment epithelium (sub-RPE) fluid at the subfoveal and macular areas—were evaluated before and two months after treatment with faricimab and aflibercept 8 mg. Subgroup analyses were performed according to AMD subtype (typical nAMD vs. polypoidal choroidal vasculopathy [PCV]) and pachychoroid characteristics (pachychoroid vs. non-pachychoroid).
Results
BCVA did not show significant changes after either faricimab or aflibercept 8 mg treatment. However, aflibercept 8 mg resulted in a significant reduction in subfoveal SRF (from 44.4% to 11.1%, P = 0.014) and macular SRF (from 85.2% to 29.6%, P < 0.0001), whereas faricimab did not produce significant anatomical improvements. No significant changes were observed in IRF or sub-RPE fluid with either treatment, possibly due to the low prevalence of the fluid at baseline. Subgroup analyses demonstrated no substantial differences in treatment response between typical nAMD and PCV, or between pachychoroid and non-pachychoroid eyes.
Conclusion
Intravitreal aflibercept 8 mg may provide short-term anatomical benefits, particularly in reducing subretinal fluid, in eyes with nAMD showing persistent or recurrent exudation after faricimab treatment during the maintenance phase, regardless of nAMD subtype or pachychoroid status.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology and Visual Science, Kochi Medical School, Kochi University, Kohasu, Oko, Nankoku, Kochi, 783-8505, Japan.
- Department of Ophthalmology and Visual Science, Kochi Medical School, Kochi University, Kohasu, Oko, Nankoku, Kochi, 783-8505, Japan. yamashk@kochi-u.ac.jp.
Zitieren
APA
Moribe, J. H., Masaoka, M., & Yamashiro, K. (2026). Aflibercept 8mg for neovascular age related macular degeneration refractory to faricimab. Japanese Journal of Ophthalmology. https://doi.org/10.1007/s10384-026-01407-3
Vancouver
Moribe JH, Masaoka M, Yamashiro K. Aflibercept 8mg for neovascular age related macular degeneration refractory to faricimab. Japanese Journal of Ophthalmology. 2026. doi:10.1007/s10384-026-01407-3
BibTeX
@article{Moribe2026,
author = {Moribe, Juliana H and Masaoka, Misa and Yamashiro, Kenji},
title = {Aflibercept 8mg for neovascular age related macular degeneration refractory to faricimab},
journal = {Japanese Journal of Ophthalmology},
year = {2026},
doi = {10.1007/s10384-026-01407-3}
}
EUVIMED